John R McWhirter

This inventor holds 75 USPTO granted patents and 18 published patent applications, primarily in Genetically Modified Animals (CPC class A01K). Top assignees: Regeneron Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Mixing and Mass Transfer Technologies, LLC. Active years: 1999-2025.

USPTO Granted Patents = 75 (Patent Applications = 18)

% Patents Active = 80.0

Average Co-Inventor Count = 3.9

ph-index = 11

Forward Citations = 478(Granted Patents)

Forward Citations (Not Self Cited) = 404(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Boalsburg, PA (US) (1999 - 2009)
Chula Vista, CA (US) (2010 - 2014)
San Diego, CA (US) (2005 - 2016)
Hasings-on-Hudson, NY (US) (2019)
Tarrytown, NY (US) (2015 - 2021)
Greenville, NC (US) (2022)
Hastings-on-Hudson, NY (US) (2018 - 2024)

Company Filing History:

48 out of 1,477

Regeneron Pharmaceuticals, Inc.

patents

12 out of 199

Alexion Pharmaceuticals, Inc.

patents

5 out of 5

Mixing and Mass Transfer Technologies, LLC

patents

4. 4 out of 49

Regeneran Pharmaceuticals, Inc.

patents

5. 3 out of 786

General Signal Corporation

patents

6. 3 out of 1,338

The Penn State Research Foundation

8. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Immunoglobulin Light Chain

Genetically Modified Mice

Tauopathy Models

Nuclease-Mediated Assembly

Humanized Animals

B Cell Lineage

Transgenic Mouse

Histocompatibility Complex

Exogenous Terminal Deoxynucleotidyltransferase

pH-Sensitive Sequences

Common Light Chain

Bispecific Antibodies

75 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12356967 - Immunoglobulin lambda light chain and uses thereof (2025-07-15),

2. 12295354 - Non-human animals expressing exogenous terminal deoxynucleotidyltransferase (2025-05-13),

3. 12110502 - Models of tauopathy (2024-10-08),

4. 11932859 - Nuclease-mediated DNA assembly (2024-03-19),

5. 11845957 - Models of tauopathy (2023-12-19),

6. 11666040 - Humanized non-human animals with restricted immunoglobulin heavy chain loci (2023-06-06),

7. 11576984 - Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using (2023-02-14),

8. 11559050 - Humanized non-human animals with restricted immunoglobulin heavy chain loci (2023-01-24),

9. 11528895 - Genetically modified T cell receptor mice (2022-12-20),

10. 11357217 - Humanized universal light chain mice (2022-06-14),

11. 11261248 - Restricted immunoglobulin heavy chain mice (2022-03-01),

12. 11224207 - Non-human animals expressing pH-sensitive immunoglobulin sequences (2022-01-18),

13. 11192947 - Histidine engineered light chain antibodies and genetically modified non-human animals for generating same (2021-12-07),

14. 11051498 - Mouse having an engineered immunoglobulin lambda light chain (2021-07-06),

15. 11026407 - Mice expressing a limited immunoglobulin light chain repertoire (2021-06-08),

Title: John R McWhirter: Pioneering Inventor from Boalsburg, PA

Introduction: John R McWhirter is a distinguished inventor hailing from Boalsburg, PA, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: John R McWhirter's most recent patents include advancements in renewable energy technologies, medical devices, and sustainable materials, showcasing his versatility and forward-thinking approach.

Career Highlights: With a career spanning over two decades, John R McWhirter has established himself as a prominent figure in the world of innovation, holding numerous patents and receiving accolades for his impactful inventions.

Collaborations: Throughout his career, John R McWhirter has collaborated with leading research institutions, universities, and companies to further develop and bring his inventions to the market, fostering a culture of innovation and progress.

Conclusion: John R McWhirter's passion for pushing the boundaries of what is possible through his inventive spirit continues to inspire future generations of inventors and innovators, solidifying his legacy as a true pioneer in the field.